 |
|
|
| |
The Farnesoid X Receptor (FXR) Agonist EDP-305 Reduces Ascites and Hepatocellular
Carcinoma Development in a Rat Model of Cirrhosis
|
| |
| |
AASLD/2017: Significant anti-fibrotic efficacy of EDP-305, a highly potent and selective farnesoid X receptor (FXR) agonist, in a rat model of thioacetamide-induced liver fibrosis and cirrhosis
EASL/2017: EDP-305, a novel and highly potent farnesoid X receptor agonist, improves liver steatosis, ballooning and non-alcoholic fatty liver disease (NAFLD) activity score (NAS) in a diet-induced murine model of non-alcoholic steatohepatitis
EASL/2017: A novel farnesoid X receptor agonist: EDP-305, reduces fibrosis progression in animal models of fibrosis
Enanta Announces New Preclinical Data on its FXR Agonist EDP-305 for Non-Alcoholic Steatohepatitis (NASH) and Primary Biliary Cholangitis (PBC) at The International Liver Congress™ 2017
Reported by Jules Levin
AASLD 2018 Nov 9-13 SF
Sarani Ghoshal1, Gunisha Arora1, Ricard Masia2, Mozhdeh Sojoodi1, Diego S. Ferriera3, Yang Li4, Guogiang Wang4, Yat Sun Or4, Li-Juan Jiang4,
Kenneth K. Tanabe1, Bryan C. Fuchs1
1Division of Surgical Oncology, 2Department of Pathology, 3Martinos Center for Biomedical Imaging,
Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States
4Enanta Pharmaceuticals, Inc., Watertown, MA, USA
|
| |
|
|
|
|
|
